Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Backs Approval of Abbott's Humira for New Use

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/28/2012 | 10:06pm CET

WASHINGTON--A federal advisory panel backed the use of an Abbott Laboratories (>> Abbott Laboratories) drug, Humira, as a treatment for patients with inflammatory bowel disease, saying many patients would benefit from treatment with the product.

Abbott is seeking expanded approval from the U.S. Food and Drug Administration for its anti-inflammatory drug Humira to treat ulcerative colitis. Humira, which had almost $8 billion in annual sales last year, currently is approved to treat rheumatoid arthritis, Crohn's Disease and other inflammatory conditions.

The drug was reviewed Tuesday by the FDA's gastrointestinal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 15 to 2 on a question that asked whether "the expected benefits outweigh the known and potential risks of Humira" for the treatment of certain patients with ulcerative colitis.

The vote amounts to a recommendation that the FDA approve the product. The FDA usually follows the advice of its panels but is not required to. The FDA declined to approve Humira for colitis last year and asked the company for additional information. The agency also said it would seek the advice of an advisory panel.

Abbott studied Humira in two clinical trials involving more than 1,000 patients. Both studies met goals showing Humira improved rates of disease remission compared to a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Patients in the studies also were being treated with older commonly used drugs for colitis including steroids.

Although the FDA agreed that the studies met their goals, the agency questioned whether the difference in remission rates of less than 10% between the Humira groups and placebo groups was "clinically meaningful." The studies showed about 17% to 19% of patients being treated with Humira achieved disease remission at eight weeks compared to about 9% of patients being treated with a placebo, according to the FDA. After one year of treatment the results were similar.

"The central issue is whether the applicant has adequately demonstrated and provided evidence of benefit sufficient to conclude that the benefit outweighs the risks of Humira for [ulcerative colitis]," the FDA said in a background memo prepared for the advisory committee meeting.

However, the majority of the panel disagreed, voting 15 to 1 saying that the differences between the drug and placebo groups were clinically meaningful.

Abbott officials and doctors who spoke on behalf of the company during the panel meeting said many patients with colitis don't respond well to currently available treatments, which also include Johnson & Johnson's (>> Johnson & Johnson) Remicade, and need an additional option. The company proposed stopping treatment in patients who don't respond to the drug after eight weeks of treatment.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

(CORRECTION: This item was corrected to show that the vote tally was 15 to 2. The original incorrectly stated 12 to 2 in the third paragraph.)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
01/21 ABBOTT LABORATORIES : New Study Demonstrates Spinal Cord Stimulation Can Reduce ..
01/20ABBOTT LABORATORIES : annual earnings release
01/19 ABBOTT LABORATORIES : Trademark Application for "FLEXIFLO" Filed by Abbott Labor..
01/18 ABBOTT : Announces European Launch of the Proclaim(TM) DRG Neurostimulation Syst..
01/17 ABBOTT LABORATORIES : New Data Confirms Abbott's Dorsal Root Ganglion Stimulatio..
01/16 ABBOTT LABORATORIES : Global Prebiotics Market 2017 - Abbott Laboratories, GNC, ..
01/12 ABBOTT LABORATORIES : Announces U.S. Launch and First Commercial Use of the New ..
01/12 ABBOTT : Announces U.S. Launch and First Commercial Use of the New EnSite(TM) Pr..
01/12 ABBOTT LABORATORIES : Trademark Application for "FRUITIFIED" Filed by Abbott Lab..
01/12 ABBOTT LABORATORIES : Trademark Application for "ZONEPERFECT INDULGENCE" Filed b..
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 3 COMPANIES WITH RECENT DIVIDEND INC : Review Using Dividend Safety Model - Janu..
01/18 Valeant Gives Up Gains
01/18 Abbott launches new neurostimulation system in Europe
01/17 DGI FOR THE DIY : 2016 Portfolio Review
01/16 Bummed About Your Abbott Labs Dividend? Here's How To Boost It
Advertisement
Financials ($)
Sales 2016 20 898 M
EBIT 2016 4 077 M
Net income 2016 1 666 M
Debt 2016 4 126 M
Yield 2016 2,56%
P/E ratio 2016 22,67
P/E ratio 2017 16,39
EV / Sales 2016 3,54x
EV / Sales 2017 3,36x
Capitalization 69 842 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 46,8 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Randel W. Woodgrift VP-Vascular, Manufacturing, Research & Development
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES5.34%69 842
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results